{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\ntemsirolimus: Given IV","id":"OG000","title":"Treatment (Temsirolimus)"}],"populationDescription":"The study concluded terminated early and patients were not followed.","reportingStatus":"POSTED","timeFrame":"Time to progression is defined as the time from registration to disease progression.","title":"Time to Progression","type":"SECONDARY"}